Vancouver, B.C. -- May 2, 2018 -- /D.M.O. Newswire/ -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FRA:LB6A) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and health and wellness products (and now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient), is pleased to announce that it has entered into a binding agreement to acquire 51% of Farmtiva LLC (“Farmtiva”), a cultivator of hemp with operations in California that provides hemp farming and distribution support for farmers and other industry participants.
Farmtiva has an exclusive partnership agreement with the not-for-profit group, Imperial Valley Conservation Research Center (“IVCRC”), and together they anticipate planting the first California hemp crop within the next three weeks. This project will be a first in California for hemp legally grown under the Agricultural Act of 2014 § 7606 (“2014 Farm Bill”) in California. As an "established agricultural research institution," under Food and Agricultural Code (FAC) Section 81000, the project is exempt from registration and may currently grow industrial hemp in California.
California defines the rules under which hemp may be grown in Division 24 of the California Food and Agricultural Code. However, California has yet to establish a mechanism by which a farmer may grow industrial hemp pursuant to local registrations that have not yet been established. Therefore, Farmtiva and Isodiol believe they are the first group to cultivate legally grown hemp in California for more than only fiber and oil seeds.
Hemp Pioneer and Farmtiva CEO, Chris Boucher said, “This partnership enables us to operate an industrial hemp research and grow operation on the grounds of the former U.S. Department of Agriculture research facility, creating new jobs and investments in the community.” The facility consists of 160 acres, with 140 acres divided into small research plots that are leased to clients including Farmtiva. In addition to the research plots, the center houses five greenhouses and a soil testing laboratory.
This is a historical moment in California hemp history, as Boucher grew a hemp crop at the same facility in 1994 when it was operated with the USDA. “We have waited over 24 years for the laws to change and now we are very excited to move California’s agriculture hemp future forward, said Boucher.”
“Farmtiva is committed to the research and development of industrial hemp, and with the IVCRC partnership, the goal is to develop a complete industrial hemp business model whereby commercialization opportunities will be implemented to ensure use of all of the hemp by-products after CBD extraction is completed, said CEO of Isodiol, Marcos Agramont.
Under the terms of this agreement, Isodiol will issue Farmtiva $1,050,000 USD in stock based on the closing price April 30th, 2018, subject to 36-month escrow guidelines, and based on Farmtiva implementing the contract rights set forth in the outstanding memorandum of understanding with IVCRC.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.